Iron oxide-enhanced MR lymphography: the evaluation of cervical lymph node metastases in head and neck cancer
- PMID: 9039596
- DOI: 10.1002/jmri.1880070111
Iron oxide-enhanced MR lymphography: the evaluation of cervical lymph node metastases in head and neck cancer
Abstract
Accurate diagnosis of cervical lymph node metastasis is challenging, even with the latest computed tomography or MR equipment and technique. The lack of definitive criteria for distinguishing metastatic from benign nodes is a serious shortcoming of current imaging options. Dextran-coated, ultrasmall superparamagnetic iron oxide is a new MR contrast agent, which accumulates in the reticuloendothelial system of lymph nodes. Small iron oxide particles are taken up by macrophages within normal functioning nodes, reducing their signal on postcontrast MR because of the magnetic susceptibility effects of iron oxide. Metastatic nodes, on the other hand, remain high in signal on postcontrast T2*-weighted gradient echo images. Early clinical experience in cancer patients suggests that iron oxide-enhanced MR lymphography is a valuable imaging technique that may improve diagnostic accuracy for nodal metastases. This article reviews development of superparamagnetic iron oxide compounds, their imaging characteristics, and clinical experience for evaluating head and neck cancer metastases.
Similar articles
-
Iron oxide-enhanced MR lymphography: initial experience.Eur J Radiol. 2000 Jun;34(3):257-64. doi: 10.1016/s0720-048x(00)00204-7. Eur J Radiol. 2000. PMID: 10927166 Review.
-
Imaging of nodal metastases in the head and neck.J Magn Reson Imaging. 1997 Sep-Oct;7(5):774-83. doi: 10.1002/jmri.1880070503. J Magn Reson Imaging. 1997. PMID: 9307901 Review.
-
Lymph node metastases: safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles--initial clinical experience.Radiology. 1998 Jun;207(3):799-808. doi: 10.1148/radiology.207.3.9609907. Radiology. 1998. PMID: 9609907 Clinical Trial.
-
MR imaging of head and neck tumors: comparison of T1-weighted contrast-enhanced fat-suppressed images with conventional T2-weighted and fast spin-echo T2-weighted images.AJR Am J Roentgenol. 1994 Jul;163(1):173-8. doi: 10.2214/ajr.163.1.8010208. AJR Am J Roentgenol. 1994. PMID: 8010208
-
Superparamagnetic iron oxide-enhanced MR imaging of head and neck lymph nodes.Radiology. 2002 Jan;222(1):239-44. doi: 10.1148/radiol.2221010225. Radiology. 2002. PMID: 11756732 Clinical Trial.
Cited by
-
The role of heparanase in lymph node metastatic dissemination: dynamic contrast-enhanced MRI of Eb lymphoma in mice.Neoplasia. 2005 Mar;7(3):224-33. doi: 10.1593/neo.04433. Neoplasia. 2005. PMID: 15799822 Free PMC article.
-
Molecular Imaging for Early-Stage Disease Diagnosis.Adv Exp Med Biol. 2023;1199:39-58. doi: 10.1007/978-981-32-9902-3_3. Adv Exp Med Biol. 2023. PMID: 37460726
-
Breast imaging. Preoperative breast cancer staging: comparison of USPIO-enhanced MR imaging and 18F-fluorodeoxyglucose (FDC) positron emission tomography (PET) imaging for axillary lymph node staging--initial findings.Eur Radiol. 2006 Oct;16(10):2153-60. doi: 10.1007/s00330-006-0276-4. Epub 2006 May 3. Eur Radiol. 2006. PMID: 16670863 Clinical Trial.
-
Evaluation of lymph node metastases in gastric cancer using magnetic resonance imaging with ultrasmall superparamagnetic iron oxide (USPIO): diagnostic performance in post-contrast images using new diagnostic criteria.Gastric Cancer. 2008;11(4):194-200. doi: 10.1007/s10120-008-0480-9. Epub 2009 Jan 8. Gastric Cancer. 2008. PMID: 19132480
-
Gadofluorine 8: initial experience with a new contrast medium for interstitial MR lymphography.MAGMA. 1999 Aug;8(3):190-5. doi: 10.1007/BF02594598. MAGMA. 1999. PMID: 10504047
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical